Tema Heart & Health ETFHRTS
Type
ETF
Peer group
Global equity
Net assets
$55.3M
Expense ratio
0.75%
1-year return
+27.8%
3 years, a year
+13.3%
5 years, a year
—
12-month yield
1.31%
Holdings
44
What it aims to do.
Tema Heart & Health ETF ( formerly, Tema GLP-1, Obesity & Cardiometabolic ETF ) (the Fund) seeks to provide long-term growth of capital.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co | 10.01% |
| Roche Holding AG | 5.46% |
| JNJ Johnson & Johnson | 4.86% |
| AstraZeneca PLC | 4.81% |
| MRK Merck & Co Inc | 4.23% |
| TMO Thermo Fisher Scientific Inc | 3.90% |
| UNH UnitedHealth Group Inc | 3.84% |
| GILD Gilead Sciences Inc | 3.62% |
| Novartis AG | 3.62% |
| ABT Abbott Laboratories | 3.37% |
More on HRTS.
- HRTS overview
- HRTS holdings
- HRTS risk
- HRTS costs
- HRTS money in and out
- HRTS share classes
- Compare HRTS with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.